Jiangsu Sinopep-Allsino Biopharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Jiangsu Sinopep-Allsino Biopharmaceutical has a total shareholder equity of CN¥2.3B and total debt of CN¥1.0B, which brings its debt-to-equity ratio to 45.8%. Its total assets and total liabilities are CN¥3.7B and CN¥1.5B respectively. Jiangsu Sinopep-Allsino Biopharmaceutical's EBIT is CN¥248.9M making its interest coverage ratio 35.1. It has cash and short-term investments of CN¥744.2M.
Key information
45.8%
Debt to equity ratio
CN¥1.04b
Debt
| Interest coverage ratio | 35.1x |
| Cash | CN¥744.18m |
| Equity | CN¥2.27b |
| Total liabilities | CN¥1.45b |
| Total assets | CN¥3.72b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 688076's short term assets (CN¥1.5B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 688076's short term assets (CN¥1.5B) exceed its long term liabilities (CN¥387.3M).
Debt to Equity History and Analysis
Debt Level: 688076's net debt to equity ratio (13%) is considered satisfactory.
Reducing Debt: 688076's debt to equity ratio has increased from 13.6% to 45.8% over the past 5 years.
Debt Coverage: 688076's debt is well covered by operating cash flow (27.3%).
Interest Coverage: 688076's interest payments on its debt are well covered by EBIT (35.1x coverage).